Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Drugs acting on the respiratory system
Icenticaftor
Другие языки:

    Icenticaftor

    Подписчиков: 0, рейтинг: 0
    Icenticaftor
    Icenticaftor.svg
    Clinical data
    Other names QBW251
    ATC code
    • none
    Identifiers
    • 3-Amino-6-methoxy-N-[(2S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl]-5-(trifluoromethyl)pyridine-2-carboxamide
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    KEGG
    Chemical and physical data
    Formula C12H13F6N3O3
    Molar mass 361.244 g·mol−1
    3D model (JSmol)
    • C[C@](CNC(=O)C1=C(C=C(C(=N1)OC)C(F)(F)F)N)(C(F)(F)F)O
    • InChI=1S/C12H13F6N3O3/c1-10(23,12(16,17)18)4-20-8(22)7-6(19)3-5(11(13,14)15)9(21-7)24-2/h3,23H,4,19H2,1-2H3,(H,20,22)/t10-/m0/s1
    • Key:USHQRIKZLHNPQR-JTQLQIEISA-N

    Icenticaftor (development code QBW251) is a drug candidate for the treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis. The drug is being developed by Novartis.

    Like ivacaftor (which is marketed as Kalydeco), icenticaftor functions by acting as a stimulator of the protein cystic fibrosis transmembrane conductance regulator (CFTR).



    Новое сообщение